escal
pandem
novel
viru
impact
global
health
effect
therapeut
option
urgent
need
evalu
vitro
antivir
effect
compound
previous
report
inhibit
coronaviru
replic
compound
current
evalu
clinic
trial
patient
report
antivir
effect
remdesivir
lopinavir
homorringtonin
emetin
viru
vero
cell
estim
effect
concentr
respect
ribavirin
favipiravir
current
evalu
clinic
trial
show
inhibit
synergi
remdesivir
emetin
observ
remdesivir
combin
emetin
may
achiev
inhibit
viral
yield
combin
therapi
may
help
reduc
effect
concentr
compound
therapeut
plasma
concentr
provid
better
clinic
benefit
within
three
month
first
identif
viru
wuhan
hubei
provinc
china
world
face
escal
pandem
signific
impact
global
health
system
economi
infect
novel
viru
may
lead
wide
rang
clinic
present
asymptomat
infect
laboratori
confirm
case
mild
sever
critic
infect
symptomat
case
respect
wu
mcgoogan
estim
symptomat
casefat
risk
scfr
among
case
wuhan
age
time
like
die
infect
age
year
estim
basic
reproduct
number
ci
li
et
al
viru
continu
spread
infect
global
popul
time
effect
vaccin
develop
fine
et
al
current
effect
antivir
compound
licens
treatment
human
coronavirus
viru
share
genet
homolog
sarscov
descend
bat
coronavirus
within
betacoronaviru
genu
antivir
compound
previous
report
show
effect
sarscov
coronavirus
may
effect
chu
et
al
de
wild
et
al
dyall
et
al
shen
et
al
cao
et
al
addit
remdesivir
prodrug
adenosin
analog
broadspectrum
antivir
activ
filovirus
paramyxovirus
coronavirus
brown
et
al
sheahan
et
al
de
wit
et
al
recent
confirm
inhibit
vitro
accord
edit
novel
coronaviru
diagnosi
treatment
plan
issu
nation
health
commiss
peopl
republ
china
option
antivir
therapi
includ
aerosol
lopinavirritonavir
ribavirin
combin
lopinavirritonavir
chloroquin
phosphat
arbidol
china
nation
health
commiss
ongo
clinic
trial
evalu
efficaci
remdesivir
variou
hivproteas
inhibitor
lopinavirritonavir
darunavir
revers
transcriptas
inhibitor
azvudin
antiinfluenza
compound
interferon
monoclon
antibodi
target
camrelizumab
tocilizumab
chines
clinic
trial
evalu
effect
compound
develop
alreadi
approv
clinic
applic
compound
previous
report
inhibit
coronaviru
replic
vitro
evalu
clinic
trial
patient
coronaviru
diseas
viru
betacovhong
isol
nasopharynx
aspir
throat
swab
confirm
patient
hong
kong
use
vero
cell
atcc
stock
viru
tcid
ml
prepar
three
serial
passag
vero
cell
infect
media
dmem
supplement
gl
dglucos
mgl
sodium
pyruv
fb
ul
penicillinstreptomycin
mm
hepe
compound
sourc
medchemexpress
sigmaaldrich
stock
prepar
dmso
mm
remdesivir
mm
favipiravir
mm
mm
tenofovir
mm
fludarabin
phosphat
mm
baloxavir
mm
chlorpromazin
hydrochlorid
mm
dalbavancin
hydrochlorid
mm
homoharringtonin
mm
lopinavir
mm
ritonavir
water
mm
emetin
dihydrochlorid
mm
galidesivir
hydrochlorid
mm
ribavirin
mm
oritavancin
diphosph
oseltamivir
carboxyl
mm
water
provid
roch
evalu
effect
compound
vitro
vero
cell
pretreat
compound
dilut
infect
media
h
prior
infect
viru
moi
antivir
compound
maintain
viru
inoculum
incub
period
inoculum
remov
incub
cell
overlaid
infect
media
contain
dilut
compound
h
incub
supernat
collect
quantifi
viral
load
tcid
assay
quantit
realtim
rtpcr
fast
viru
master
mix
follow
method
describ
chu
et
al
fourparamet
logist
regress
graphpad
prism
use
fit
doserespons
curv
determin
effect
concentr
ec
compound
inhibit
viral
replic
cytotoxicti
select
compound
evalu
vero
cell
use
luminesc
cell
viabil
assay
promega
among
compound
test
remdesivir
lopinavir
homoharringtonin
emetin
dihydrochlorid
found
inhibit
replic
vero
cell
ec
tabl
importantli
observ
compound
current
undergo
clinic
trial
ribavirin
favipiravir
oseltamivir
baloxavir
show
appar
antivir
effect
viru
vitro
concentr
tabl
remdesivir
adenosin
analogu
shown
inhibit
human
coronavirus
sarscov
merscov
brown
et
al
sheahan
et
al
de
wit
et
al
current
evalu
phase
clinic
trial
recent
studi
fit
viral
load
linear
scale
eg
percentag
inhibit
increas
concentr
remdesivir
report
ec
viru
fit
viral
load
logarithm
scale
log
tcid
ml
log
viral
rna
copiesml
increas
concentr
remdesivir
determin
ec
respect
fig
tabl
two
mutat
rnadepend
rna
polymeras
murin
hepat
viru
previous
report
confer
resist
remdesivir
agostini
et
al
due
insert
delet
two
conserv
residu
map
isol
gisaid
use
experi
remain
sensit
remdesivir
adenosin
analogu
galidesivir
tenofovor
fludarabin
phosphat
nucleosid
analogu
favipiravir
ribavirin
inhibit
viral
replic
tabl
howev
nucleosid
analogu
requir
metabol
activ
triphosph
form
host
cellular
nucleosid
kinas
may
differ
among
cell
type
evalu
effect
nucleosid
analogu
primari
human
airway
epitheli
cell
would
facilit
interpret
result
lopinavir
combin
ritonavir
fda
approv
proteas
inhibitor
lopinavir
potent
inhibit
ritonavir
vitro
show
poor
bioavail
vivo
ritonavir
inhibit
proteas
also
host
cytochrom
enzym
metabol
lopinavir
kempf
et
al
lopinavir
ritonavir
combin
prolong
bioavail
lopinavir
vivo
sham
et
al
lopinavir
ritonavir
show
antivir
effect
sarscov
merscov
vitro
mean
ec
rang
de
wild
et
al
lopinavirritonavir
combin
ribavirin
use
previous
treat
sarscov
patient
nonrandom
clinic
trial
less
sar
patient
develop
ard
death
receiv
combin
lopinavirritonavir
ribavirin
histor
control
receiv
ribavirin
corticosteroid
chu
et
al
efficaci
lopinavir
ritonavir
without
ribavirin
current
evalu
patient
random
control
trial
agreement
previou
report
observ
antivir
effect
lopinavir
ec
ritonavir
vitro
fig
tabl
patient
treat
mg
lopinavir
mg
ritonavir
twice
daili
may
reach
minim
lopinavir
serum
concentr
iqr
ec
viru
vitro
lopezcort
et
al
current
lopinavirritonavir
mg
twice
daili
without
ribavirin
part
recommend
treatment
manag
patient
china
china
nation
health
commiss
recent
random
control
trial
report
signific
benefit
lopinavirritonavir
hospit
patient
standard
care
time
clinic
improv
mortal
day
viral
load
variou
time
point
compar
two
group
combin
therapi
lopinavir
effect
compound
viru
may
increas
synergi
reduc
inhibitori
concentr
lopinavir
homoharringtonin
plant
alkaloid
deriv
cephalotoxu
fortunei
exhibit
antitumor
activ
bind
ribosom
site
inhibit
protein
translat
lead
rapid
loss
shortliv
protein
includ
cmyc
promot
surviv
leukemia
cell
dong
et
al
lu
wang
omacetaxin
semisynthet
form
homoharringtonin
approv
fda
treatment
chronic
myeloid
leukemia
homoharringtonin
also
report
exhibit
potent
antivir
activ
herpesvirus
varicellazost
viru
herp
simplex
pseudorabi
viru
coronavirus
porcin
epidem
diarrhea
viru
murin
hepat
viru
rhabdovirus
vsv
rabi
viru
virus
hepat
b
viru
newcastl
diseas
viru
echoviru
dong
et
al
andersen
et
al
observ
homoharringtonin
inhibit
ec
fig
tabl
previou
pharmacokinet
studi
show
patient
treat
mgm
omacetaxin
everi
h
subcutan
inject
may
reach
maxim
plasma
concentr
ngml
ngml
day
respect
nemuna
et
al
ec
viru
vitro
emetin
protein
synthesi
inhibitor
use
antiprotozoan
approv
treatment
ameobiasi
also
inhibit
malaria
bind
ribosom
e
site
plasmodium
falciparum
grollman
wong
et
al
howev
potenti
cardiotox
restrict
clinic
use
recent
year
found
process
antivir
activ
broad
rang
rna
dna
virus
includ
zika
viru
ebolaviru
cytomegaloviru
rabi
viru
echoviru
buffalo
poxviru
bovin
herpesviru
pest
de
petit
rumin
viru
newcastl
diseas
viru
herp
simplex
metapneumoviru
rift
valley
fever
viru
influenza
andersen
et
al
chave
valadao
et
al
khandelw
et
al
macgibeni
et
al
mukhopadhyay
et
al
yang
et
al
emetin
also
identifi
inhibit
sarscov
merscov
vitro
ec
report
low
micromolar
rang
dyall
et
al
shen
et
al
observ
emetin
around
may
effect
inhibit
viru
replic
fig
tabl
therapeut
plasma
concentr
emetin
may
reach
regenth
et
al
ec
viru
vitro
toxic
plasma
concentr
regenth
et
al
tabl
antivir
activ
compound
vero
cell
reduc
effect
concentr
individu
compound
maxim
therapeut
plasma
concentr
explor
combin
effect
remdesivir
emetin
vitro
drug
interact
evalu
use
checkerboard
assay
serial
dilut
remdesivir
emetin
combin
remdesivir
combin
emetin
may
achiev
inhibit
viral
yield
test
vivo
fig
loew
addit
model
bliss
independ
model
malyutina
et
al
use
analys
interact
two
compound
use
synergyfind
ianevski
et
al
remdesivir
emetin
combin
yield
loew
synergi
score
fig
bliss
synergi
score
fig
confirm
antivir
activ
four
compound
report
inhibit
coronaviru
replic
vitro
result
suggest
combin
therapi
may
help
reduc
effect
concentr
maxim
therapeut
plasma
concentr
urgent
research
need
identifi
optim
dose
combin
effect
compound
viru
better
clinic
benefit
